Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
View Patent ↗Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
1. A method of treating complex regional pain syndrome comprising orally administering zoledronic acid to a human being in need thereof, wherein the human being receives about 400 mg to about 500 mg of the zoledronic acid within a period of six months.
2. The method of claim 1 , wherein the human being receives the zoledronic acid no more often than once daily.
3. The method of claim 1 , wherein the human being does not eat food or drink beverage for at least 30 minutes after the zoledronic acid is administered.
4. The method of claim 1 , wherein the human being does not eat food or drink beverage for at least 30 minutes before the zoledronic acid is administered.
5. The method of claim 1 , wherein the human being does not eat food or drink beverage for at least 60 minutes after the zoledronic acid is administered.
6. The method of claim 1 , wherein the human being does not eat food or drink beverage for at least 60 minutes before the zoledronic acid is administered.
7. The method of claim 1 , wherein the zoledronic acid is orally administered no more often than once weekly.
8. The method of claim 1 , wherein the zoledronic acid is orally administered weekly.
9. The method of claim 1 , wherein the zoledronic acid is orally administered 2 to 5 times in a month.
10. The method of claim 1 , wherein the zoledronic acid is orally administered once a month, or less frequently.
11. The method of claim 1 , wherein the zoledronic acid is orally administered within a period of three months.
12. The method of claim 1 , wherein the zoledronic acid is orally administered within a period of two months.
13. The method of claim 1 , wherein the zoledronic acid is orally administered weekly for one to two months.
14. The method of claim 1 , wherein at least about 300 mg of the zoledronic acid is administered within the first month of treatment.
15. The method of claim 1 , wherein the zoledronic acid is administered in multiple individual doses each comprising about 140 mg to about 180 mg of the zoledronic acid.
16. The method of claim 1 , wherein a total of about 450 mg to about 500 mg of the zoledronic acid is administered.
17. The method of claim 1 , wherein the zoledronic acid is orally administered in a dosage form containing at least 10% zoledronic acid.
18. The method of claim 1 , wherein at least three doses of the zoledronic acid are orally administered to the human being.
19. The method of claim 1 , wherein three doses of about 150 mg to about 165 mg of the zoledronic acid are orally administered within a period of two months.
20. The method of claim 1 , wherein two or three doses of about 100 mg to about 150 mg of the zoledronic acid are orally administered within a period of two months.
21. The method of claim 1 , wherein two doses of about 200 mg to about 250 mg of the zoledronic acid are orally administered within a period of two months.
22. The method of claim 1 , wherein the human being is suffering from complex regional pain syndrome Type I.
23. The method of claim 1 , wherein the human being is suffering from complex regional pain syndrome Type II.
24. The method of claim 1 , wherein the human being experiences pain relief for at least 48 hours.
25. The method of claim 1 , wherein at least some of the zoledronic acid is in a salt form.
26. The method of claim 1 , wherein the zoledronic acid is orally administered in a dosage form comprising water.
27. The method of claim 1 , wherein the zoledronic acid is orally administered in a dosage form comprising magnesium stearate.